UCB SA (EBR:UCB)
Belgium · Delayed Price · Currency is EUR | Market Cap | 45.86B +54.0% |
| Revenue (ttm) | 7.74B +25.8% |
| Net Income | 1.56B +46.3% |
| EPS | 8.03 +46.5% |
| Shares Out | 190.36M |
| PE Ratio | 30.00 |
| Forward PE | 22.51 |
| Dividend | 1.45 (0.61%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 181,677 |
| Average Volume | 235,373 |
| Open | 242.40 |
| Previous Close | 240.90 |
| Day's Range | 240.40 - 242.90 |
| 52-Week Range | 152.95 - 289.50 |
| Beta | 0.17 |
| RSI | 50.40 |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial StatementsNews
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Psoriatic Arthritis Trial
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Psoriatic Arthritis Trial
Cullinan jumps after UCB acquires Candid Therapeutics
Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held Candid Therapeutics. Cizutamig, Candid’s lead investigational asset, is “pos...
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline
(RTTNews) - United Community Banks, Inc. (UCB),on Sunday agreed to buy Candel Therapeutics, Inc. (CADL) for up to $2.2 billion, aiming to strengthen its pipeline of treatments for immune-related disea...
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
Insider Sell: Richard Bradshaw Sells Shares of United Community Banks Inc (UCB)
Insider Sell: Richard Bradshaw Sells Shares of United Community Banks Inc (UCB)
UCB: United Community Bank CFO to Retire, Transition Underway
UCB: United Community Bank CFO to Retire, Transition Underway
UCB Q1 2026 Earnings Call Transcript
UCB Q1 2026 Earnings Call Transcript
United Community Banks Inc (UCB) Q1 2026 Earnings Call Highlights: Strong Financial Performance ...
United Community Banks Inc (UCB) Q1 2026 Earnings Call Highlights: Strong Financial Performance and Strategic Growth Initiatives
UCB to acquire Neurona Therapeutics
UCB (UCBJF) announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Th...
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Sarita Kapila downgraded UCB (UCBJF) to Equal Weight from Overweight with an unchanged price target of EUR 260. The firm sees a balanced risk/reward at current share…
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.
UCB SA Slides: H2 2025
UCB SA has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.
UCB SA Slides: H2 2025
UCB SA has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
UCB initiated with an Outperform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of UCB (UCBJF) with an Outperform rating and EUR 340 price target The firm launched coverage of the neuroscience biotech sector with a…
UCB price target raised to EUR 304 from EUR 255 at Goldman Sachs
Goldman Sachs raised the firm’s price target on UCB (UCBJF) to EUR 304 from EUR 255 and keeps a Buy rating on the shares.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.
UCB SA Slides: 44th Annual J.P. Morgan Healthcare Conference
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.